Eli Lilly's stock is currently outperforming the S&P 500, indicating strong market performance. Investors are increasing their holdings, suggesting confidence in the stock's future. The stock is considered undervalued based on its PEG ratio, which could attract more investors. However, potential policy and pricing risks could impact future performance, but these are not immediate concerns.